Source: Journal of clinical endocrinology & metabolism. Unidade: FM
Subjects: FEOCROMOCITOMA, BRASILEIROS, METÁSTASE NEOPLÁSICA, MUTAÇÃO GENÉTICA
ABNT
FAGUNDES, Gustavo F. C et al. Evidence for a Founder Effect of SDHB Exon 1 Deletion in Brazilian Patients With Paraganglioma. Journal of clinical endocrinology & metabolism, v. 108, n. 8, p. 2105-2114, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/54605. Acesso em: 22 ago. 2024.APA
Fagundes, G. F. C., Freitas-Castro, F., Santana, L. S., Afonso, A. C. F., Petenuci, J., Funari, M. F. A., et al. (2023). Evidence for a Founder Effect of SDHB Exon 1 Deletion in Brazilian Patients With Paraganglioma. Journal of clinical endocrinology & metabolism, 108( 8), 2105-2114. doi:10.1210/clinem/dgad028NLM
Fagundes GFC, Freitas-Castro F, Santana LS, Afonso ACF, Petenuci J, Funari MFA, Guimaraes AG, Ledesma FL, Xavier ACL, Mendonca BB de. Evidence for a Founder Effect of SDHB Exon 1 Deletion in Brazilian Patients With Paraganglioma [Internet]. Journal of clinical endocrinology & metabolism. 2023 ; 108( 8): 2105-2114.[citado 2024 ago. 22 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54605Vancouver
Fagundes GFC, Freitas-Castro F, Santana LS, Afonso ACF, Petenuci J, Funari MFA, Guimaraes AG, Ledesma FL, Xavier ACL, Mendonca BB de. Evidence for a Founder Effect of SDHB Exon 1 Deletion in Brazilian Patients With Paraganglioma [Internet]. Journal of clinical endocrinology & metabolism. 2023 ; 108( 8): 2105-2114.[citado 2024 ago. 22 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54605